Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
NCT06072066 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2024-08-27
Summary
The purpose of this study is to evaluate how supplementation will alter the skin and the gut barrier and inflammation in those with rosacea.
Conditions
- Rosacea
- Systemic Inflammation
Interventions
- DIETARY_SUPPLEMENT
-
Skin Barrier Oral Supplement
Supplment powder
Sponsors & Collaborators
-
Integrative Skin Science and Research
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 30 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-11-22
- Primary Completion
- 2024-12-31
- Completion
- 2024-12-31
Countries
- United States
Study Locations
More Related Trials
-
Determinants of Chronic Inflammatory Skin Disease Trajectories
NCT05928169 ·Status: RECRUITING
-
DERMATOMICS: Identifying Regulators of Skin Homeostasis
NCT06894654 ·Status: RECRUITING
-
Assessment of the Rosacea Prevalence in the General Population
NCT02292797 ·Status: COMPLETED
-
Effects of Topical SLPI on Skin Wounds
NCT00005569 ·Status: COMPLETED ·Phase: PHASE1
-
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
NCT04864886 ·Status: RECRUITING
-
Nurses' Health Study and Health Professionals Follow-Up Study (Dermatological Component)
NCT03253666 ·Status: COMPLETED
-
Ruxolitinib in Seborrheic Dermatitis
NCT05787860 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate
NCT06936215 ·Status: RECRUITING ·Phase: PHASE3
-
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
NCT05270668 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Characterization and Functionality of Calcium Channels Cav1.4 of Th17 Lymphocytes in Human With Psoriasis
NCT04459780 ·Status: COMPLETED ·Phase: NA
-
Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
NCT06857240 ·Status: RECRUITING ·Phase: PHASE2
-
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
NCT01651143 ·Status: COMPLETED ·Phase: PHASE2
-
Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis
NCT00667134 ·Status: COMPLETED
-
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
NCT05189925 ·Status: RECRUITING ·Phase: PHASE1
-
Cellular and Molecular Biomarkers in Patients With Lichen Planus
NCT06451744 ·Status: RECRUITING ·Phase: NA
-
Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?
NCT03636763 ·Status: UNKNOWN
-
Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
NCT00709878 ·Status: COMPLETED
-
Sunscreen RV 2457C in Photoinduced CLE
NCT00470912 ·Status: COMPLETED ·Phase: PHASE3
-
Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis
NCT00668473 ·Status: COMPLETED
-
Methods Validation Assessment for Study of Inflammatory Skin Disease
NCT03796806 ·Status: COMPLETED
-
Oral Type I Collagen for Relieving Scleroderma
NCT00005675 ·Status: COMPLETED ·Phase: PHASE2
-
The Role of Skin Microbiota in Hepatic or Renal Pruritus
NCT05604469 ·Status: UNKNOWN
-
A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis
NCT05300932 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions
NCT01276314 ·Status: COMPLETED ·Phase: NA
-
Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin
NCT00697034 ·Status: TERMINATED ·Phase: PHASE4